RESUMEN
The medical records of 49 dogs with spontaneously occurring malignant tumors treated with doxorubicin-based chemotherapy protocols were evaluated for hematological toxicity. Protocols included vincristine, doxorubicin, and cyclophosphamide (VAC); 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); doxorubicin and cyclophosphamide (AC); and doxorubicin and dacarbazine (ADIC). Prevalence of Grades 1, 2, or 3 toxicities were less than 30%, and the prevalence of Grade 4 toxicity alone was less than 5%. The frequency of sepsis was less than 2.5% in dogs treated with VAC, FAC, or AC, and it was 15% in dogs treated with ADIC. There were no significant differences in the prevalence or severity of hematological toxicity caused by VAC or AC. Five-fluorouracil, doxorubicin, and cyclophosphamide caused significantly more severe neutropenia than VAC or AC. The low prevalence of hematological complications makes these protocols acceptable for use in practice.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Doxorrubicina/efectos adversos , Neoplasias/veterinaria , Animales , Perros , Doxorrubicina/administración & dosificación , Femenino , Recuento de Leucocitos/efectos de los fármacos , Recuento de Leucocitos/veterinaria , Masculino , Neoplasias/tratamiento farmacológico , Recuento de Plaquetas/efectos de los fármacos , Recuento de Plaquetas/veterinaria , Registros/veterinaria , Estudios RetrospectivosRESUMEN
OBJECTIVE: To determine effects of dietary cysteine on blood sulfur amino acids (SAA), reduced glutathione (GSH), oxidized glutathione (GSSG), and malondialdehyde (MDA) concentrations in cats. ANIMALS: 12 healthy adult cats. PROCEDURE: Cats were fed diets with a nominal (0.50 g/100 g dry matter [DM]), moderate (1.00 g/100 g DM), or high (1.50 g/100 g DM) cysteine content in a 3 X 3 Latin square design with blocks of 8 weeks' duration. Venous blood samples were collected after each diet had been fed for 4 and 8 weeks, and a CBC and serum biochemical analyses were performed; poikilocyte, reticulocyte, and Heinz body counts were determined; and MDA, GSH, GSSG, and SAA concentrations were measured. RESULTS: Blood cysteine and MDA concentrations were not significantly affected by dietary cysteine content. Blood methionine, homocysteine, and GSSG concentrations were significantly increased when cats consumed the high cysteine content diet but not when they consumed the moderate cysteine content diet, compared with concentrations obtained when cats consumed the nominal cysteine content diet. Blood GSH concentrations were significantly increased when cats consumed the moderate or high cysteine content diet. CONCLUSIONS: Increased dietary cysteine content promotes higher blood methionine, homocysteine, GSH, and GSSG concentrations in healthy cats. CLINICAL RELEVANCE: Supplemental dietary cysteine may be indicated to promote glutathione synthesis and ameliorate adverse effects of oxidative damage induced by disease or drugs.
Asunto(s)
Aminoácidos/sangre , Fenómenos Fisiológicos Nutricionales de los Animales , Gatos/sangre , Cisteína/farmacología , Glutatión/sangre , Malondialdehído/sangre , Azufre/sangre , Animales , Cuidados Críticos , Suplementos Dietéticos , Femenino , Masculino , Estrés OxidativoRESUMEN
OBJECTIVE: To determine the effectiveness and safety of asparaginase administered s.c. versus i.m. for treatment of multicentric lymphoma in dogs receiving doxorubicin. DESIGN: Prospective study. ANIMALS: 49 dogs with multicentric lymphoma. PROCEDURE: Dogs were treated with doxorubicin every 3 weeks, for a total of 5 treatments, and were given 3 weekly treatments of asparaginase, s.c. or i.m. Using high-performance liquid chromatography, mean plasma asparagine, aspartic acid, glutamine, and glutamic acid concentrations were determined in dogs before and during treatment with asparaginase (10,000 U/m2 of body surface area, once a week for 3 weeks). Asparaginase was administered s.c. in 23 dogs and i.m. in 26 dogs. Variables evaluated included time to response to chemotherapy, remission and survival times, and clinical and serum biochemical indicators of toxicoses. RESULTS: Using the World Health Organization's staging system for lymphoma, 30 dogs were in clinical stage III and 19 were in clinical stage IV. One week after asparaginase treatment, plasma asparagine concentrations were low and plasma aspartic acid, glutamine, and glutamic acid concentrations were high. Differences in plasma amino acid concentrations were not found between s.c. and i.m. groups. For dogs in clinical stage IV, i.m. administration of asparaginase significantly decreased the number of days to complete remission, compared with s.c. administration (8 vs 17 days, respectively). For dogs in clinical stage III, i.m. administration favorably increased the duration of first remission (191 vs 103 days) and survival time (289 vs 209 days). Overall, dogs treated i.m. had a faster response to chemotherapy (9 vs 15 days), a longer remission (191 vs 109 days), and a longer survival time (286 vs 198 days), compared with all dogs treated s.c. Asparaginase toxicoses were not observed regardless of the route of administration. CLINICAL IMPLICATIONS: For dogs with multicentric lymphoma that are receiving doxorubicin, i.m. treatment with asparaginase is more effective than s.c. treatment.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Asparaginasa/administración & dosificación , Enfermedades de los Perros/tratamiento farmacológico , Doxorrubicina/uso terapéutico , Linfoma/veterinaria , Animales , Perros , Quimioterapia Combinada , Femenino , Inyecciones Intramusculares/veterinaria , Inyecciones Subcutáneas/veterinaria , Linfoma/tratamiento farmacológico , Masculino , Estudios Prospectivos , Inducción de Remisión , Análisis de Supervivencia , Factores de TiempoRESUMEN
The medical records of 34 dogs (median age, eight years) with colorectal mucosal lesions were reviewed. Hematochezia was the most common (82%) presenting sign. Most dogs (79%) presented with solitary masses located in the rectum. After histological review, 12 masses were classified as adenomatous polyps and 22 as carcinoma in situ. Recurrence of clinical signs were common (41%), and malignant transformation of the tumor was documented in 18% of the cases. A higher recurrence rate and malignant transformation occurred in dogs presented with multiple masses or diffuse disease and in dogs initially diagnosed with carcinoma in situ.
Asunto(s)
Adenoma/veterinaria , Carcinoma in Situ/veterinaria , Neoplasias Colorrectales/veterinaria , Enfermedades de los Perros/diagnóstico , Pólipos/veterinaria , Adenoma/diagnóstico , Adenoma/patología , Animales , Carcinoma in Situ/diagnóstico , Carcinoma in Situ/patología , Transformación Celular Neoplásica/patología , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/patología , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/patología , Perros , Femenino , Masculino , Recurrencia Local de Neoplasia/veterinaria , Pólipos/diagnóstico , Pólipos/patología , Prevalencia , Estudios RetrospectivosRESUMEN
OBJECTIVE: To determine response rate and remission as well as survival times for dogs with multicentric lymphoma treated first with doxorubicin alone or in combination with asparaginase and then with cyclophosphamide, vincristine sulfate, and prednisone (CVP) and to identify prevalence of toxicoses associated with this protocol and factors associated with prognosis. DESIGN: Retrospective case series. ANIMALS: 121 dogs. PROCEDURE: Variables evaluated for prognostic value were initial response rate to chemotherapy, age, breed, sex, body weight, histologic grade, clinical stage and substage, previous corticosteroid treatment, and serum calcium concentration. RESULTS: Median overall remission and survival times for all 121 dogs were 205 and 237 days, respectively. Response rate (complete or partial response) was 88%. Ten dogs were hospitalized because of toxicoses associated with doxorubicin, and 19 dogs were hospitalized because of toxicoses associated with CVP. Asparaginase favorably influenced the initial response rate, but did not significantly influence overall remission of survival times. Initial response rate to chemotherapy, body weight, clinical substage, and serum calcium concentration was found to have prognostic value. CLINICAL IMPLICATIONS: For dogs with multicentric lymphoma, treatment with doxorubicin alone or in combination with asparaginase and then with CVP resulted in an acceptable response rate and low prevalence of toxicoses.